Cat. No. 4242
Chemical Name: 6-(4-Chlorophenyl)-3-[3-methoxy-4-[
Biological ActivitySelective melanin-concentrating hormone receptor 1 (MCH1) antagonist (IC50 = 9.3 nM). Displays antiobesity and antidepressant-like effects in rats and mice. Orally active.
Licensing InformationSold for research purposes under agreement from GlaxoSmithKline.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Gehlert et al (2009) Preclinical evaluation of melanin-concentrating hormone receptor 1 antagonism for the treatment of obesity and depression. J.Pharmacol.Exp.Ther. 329 429. PMID: 19182070.
Rivera et al (2008) Melanin-concentrating hormone receptor 1 antagonists: a new perspective for the pharmacologic treatment of obesity. Curr.Med.Chem. 15 1025. PMID: 18393860.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses GW 803430 from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: GW 803430, supplier, glaxosmithkline, melanin, concentrating, hormone, receptors, mchr1, antagonists, antiobesity, obese, GW803430, Tocris Bioscience, Melanin-concentrating Hormone Receptor Antagonist products
Find multiple products by catalog number
New Products in this Area
Non-peptide apelin receptor agonistBML 111
FPR2 (lipoxin A4 receptor) agonistAmylin (rat)
Potent endogenous peptide agonist for amylin, calcitonin, CGRP and adrenomedullin receptorsCalcitonin (human)
Endogenous calcitonin receptor agonist; inhibits bone resorptionSpexin
Potent GAL2/3 agonist; exhibits anxiolytic effects in vivoMM 54
Potent apelin receptor antagonistMSG 606
Potent human MC1 receptor antagonist; also MC3 and MC5 partial agonist
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.